Sedalia
FDA Label NDC 0220-9332

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Laboratoires Boiron for the product Sedalia (NDC 0220-9332). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding otc - active ingredient, otc - purpose, indications & usage, otc - stop use, otc - ask doctor, otc - when using, otc - keep out of reach of children, description, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Otc - Active Ingredient

Aconitum napellus 6C, Belladona 6C, Calendula officinalis 6C, Chelidonium majus 6C, Jequirity 6C, Viburnum opulus 6C

Indications & Usage

For temporary relief of nervousness, hypersensitivity and irritability due to stress.

Otc - Stop Use

Stop use and ask a doctor if symptoms persist continuously for more than 2 weeks or worsen.

Otc - Ask Doctor

Ask a doctor before use in children younger than 12 years of age.


Otc - When Using

If pregnant or breast-feeding, ask a health professional before use.

Otc - Keep Out Of Reach Of Children

Keep out of reach of children

Description

Directions: (adults and children 12 years of age and older): Allow 3 tablets to dissolve in the mouth 3 times a day.

Storage And Handling

Store at 68-77 o F (20-25 o C)

Drug Interactions

Non habit forming, no drug interactions

Inactive Ingredient

Croscarmellose sodium, lactose, magnesium stearate.

Otc - Questions

Questions, Comments
www.boironusa.com
[email protected]
1-800-BOIRON-1
(1-800-264-7661)

Boiron Information Center
6 campus Bouelvard
Newtown Square, PA
19073-3267

How Supplied

60 tablets

Warnings


Dosage & Administration

Adult and children 12 years of age and older: dissolve 2 tablets in the mouth 3 times a day.

* Please review the disclaimer below.